News | August 07, 2024
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The company had earlier announced about the approval received from the MHRA for Liraglutide
Subscribe To Our Newsletter & Stay Updated
